Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aurix is an autologous platelet-rich plasma (PRP) gel used as a topical wound treatment. It is created from a patient’s own blood at the point of care and applied directly to chronic non-healing wounds such as diabetic foot ulcers, venous leg ulcers, and pressure injuries. The mechanism of action involves concentrating and activating the patient's platelets to release growth factors that stimulate tissue repair and accelerate healing. By utilizing autologous PRP, Aurix reduces the risk of immune rejection or allergic reaction. Clinical evidence supports its efficacy in improving healing rates for chronic ulcerations compared to standard care[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aurix.